The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 16, 2008, Pages 2759-2772

  Elmer, Lawrence W ^a   Bertoni, John M ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Levodopa; Monoamine oxidase inhibitor; Parkinson's disease; Selegiline

Indexed keywords

ANTIDEPRESSANT AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PLACEBO; RASAGILINE; SELEGILINE; TOCOPHEROL;

ADJUVANT THERAPY; ANOREXIA; AUTONOMIC DYSFUNCTION; BALANCE IMPAIRMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FIRST PASS EFFECT; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; INFECTION; MEAL; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INDANS; LEVODOPA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 56749085833     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2759     Document Type: Review

References (76)

1. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005
2. Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. Can Med Assoc J 2003;168:293-301
3. Marjama-Lyons JM, Koller WC. Parkinson's disease. Update in diagnosis and symptom management. Geriatrics 2001;56:24-30
4. Dewey RB Jr. Management of motor complications in Parkinson's disease. Neurology 2004;62(Suppl 4):S3-7
5. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-30
6. Fahn S. Developments in Parkinson's disease therapy. N Am Pharmacother 2004;2:186-7
7. Henchcliffe C, Schumacher HC, Burgut FT. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 2005;5:811-21
8. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33:91-102
9. Fowler CI, O'Carroll A, Tipton KF. Deamination of dopamine by monoamine oxidase A and B in rat and in man. In: Tipton KF, Dostert P, Strolin Benedetti M, editors, Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. London: Academic Press; 1984. p. 393-402
10. Foley P, Gerlach M, Youdim MBH, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000;6:25-47
11. Bertoni J, Elmer L. The role of MAO-B inhibitors in the treatment of Parkinson's disease. In: Ebadi M, Pfeiffer RF, editors, Parkinson's disease. Boca Raton, FL: CRC Press; 2005. p. 691-704
12. Knoll J. The pharmacology of selegiline ((-) deprenyl). New aspects. Acta Neurol Scand Suppl 1989;126:83-91
13. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349-65
14. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97
15. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236-9
16. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978;57:33-8
17. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand Suppl 1989;126:103-11
18. Mercuri NB, Scarponi M, Bonci A, et al. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 1997;17:2267-72
19. Knoll J. R-(-)-Deprenyl (selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm Suppl 1987;25:45-66
20. Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988;11:387-400
21. Mann J, Gershon S. L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 1980;26:877-82
22. Varga E, Tringer L. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCI, 'E-250'). Acta Med Acad Sci Hung 1967;23:289-95
23. Lew MF. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Rev Neurother 2005;5:705-12
24. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1241-55
25. Lieberman A. Long-term experience with selegiline and levodopa in Parkinson's disease. Neurology 1992;42(4 Suppl 4):32-6
26. Bar AMO, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004;355:169-72
27. Ebadi M, Sharma S, Shavali S, El Refaey H. Neuroprotective actions of selegiline. J Neurosci Res 2002;67:285-9
28. Takahata K, Shimazu S, Katsuki H, et al. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm 2006;113:151-8
29. Abu-Raya S, Blaugrund E, Trembovler V, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res 1999;58:456-63
30. Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002;24:675-82
31. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1 (R)-aminoindan. J Neurochem 2002;82:913-23
32. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83
33. Shoulson I; Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Ann Neurol 1998;44(3 Suppl 1):S160-6
34. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
35. Olanow CW. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology 1996;47:S210-6
36. Abu-Raya S, Tabakman R, Blaugrund E, et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 2002;434:109-16
37. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004;24:1295-305
38. Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 1981;73:65-74
39. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45:878-94
40. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 1998;52:287-300
41. AZILECT. Package insert. Kfar Saba, Israel: Teva Pharmaceutical Industries Ltd; 2006
42. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59: 1937-43
43. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
44. Youdim MB, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001;939:450-8
45. Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326:105-8
46. Maruyama W, Akao Y, Youdim MBH, et al. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001;78:727-35
47. Rascol O, Olanow W. ADAGIO: a prospective, double-blind, delayed-start study to examine the potential disease-modifying effect of rasagiline in early Parkinson's disease. Eur J Neurol 2008;15(Suppl. 3):129
48. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial. Ann Neurol 2002;51:604-12
49. Pålhagen S, Heinonen E, Hågglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-6
50. Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999;6:141-50
51. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311:1602-7
52. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998;316:1191-6
53. Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 1999;14:246-51
54. Bogner RH, Wilkosz MF. Fast-dissolving tablets. 2002. Available from: http://www.uspharmacist.com/oldformat.asp?url=newlook/files/Feat/ FastDissolving.htm&pub_id=8&article_id=842 [Last accessed 2005 July 19]
55. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-82
56. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41:661-80
57. Zelapar® (Selegiline Hydrochloride) Orally Disintegrating Tablets. Package insert. Aliso Viejo, CA: Valeant Pharmaceuticals International; 2006
58. Waters CH, Sethi KD, Hauser RA, et al. and the Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-32
59. Cedarbaum JM, Toy LH, Green-Parsons A. L-Deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations. Clin Neuropharmacol 1991;14:228-34
60. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. Clin Neuropharmacol 2007;30:295-300
61. Lew MF, Pahwa R, Leehey M, et al.; the Zydis Selegiline Study Group. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23:741-50
62. Lew M, Kricorian G. Long-term treatment of Parkinson's disease with a novel MAO-B inhibitor: analysis of safety and efficacy. J Neurol Sci 2005;238(Suppl 1):S363
63. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO Study. Arch Neurol 2005;62:241-8
64. The Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. Mov Disord 2005;20(Suppl 10):S138
65. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, Study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-54
66. Giladi N, Rascol O, Brooks DJ, et al. Largo Study Group. Rasagiline treatment can improve freezing of gait in advanced Parkinson's disease: a prospective randomized, double blind, placebo and entacapone controlled study. Neurology 2004;62(Suppl 5):A329-30
67. Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006;248:78-83
68. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-7
69. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95
70. Goetz CG. Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(Suppl 4):S1-166
71. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-39
72. Eldepryl (Selegiline Hydrochloride): Package insert. Somerset Pharmaceuticals; 1998
73. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-7
74. Lew MF, Pahwa R, Leehey M, et al. The Zydis Selegiline Study Group. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23:741-50
75. Panisset M, Schwid S, Ondo W, et al. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease. Mov Disord 2007;223(Suppl 16):S105
76. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. Clin Neuropharmacol 2007;30:295-300